PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 29 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
Used as a standard of care for much of the 20th century, though its efficacy and safety remain topics of debate [PMID:10069797, PMID:30066080].
Indicated for ventricular rate control in atrial fibrillation [PMID:30725648, PMID:3069207].
The isolated compound desrhamnosyl acteoside significantly reduced pro-inflammatory cytokines (IL-6, IL-8) and chemokines (CCL17, CCL22) in HaCaT keratinocytes and 3D human skin models [PMID:40869065].
Safety & adverse effects
Evidence summary
PubMed sources
- 1.PMID: 10069797 (1999) — Digitalis. · Circulation
- 2.PMID: 30725648 (2026) — Digitalis purpurea. · The American journal of cardiology
- 3.PMID: 30066080 (2018) — Clinical Use of Digitalis: A State of the Art Review. · American journal of cardiovascular drugs : drugs, devices, and other interventions
- 4.PMID: 34036088 (2021) — A case of intoxication with tea made from Digitalis purpurea. · Global cardiology science & practice
- 5.PMID: 3069207 (1988) — Digitalis: dead or alive? · Cardiology
- 6.